MyFinsight
Home
Blog
About
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$14,608K
Free Cash flow
-$41,739K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Stockbased compensation expense
Right-of-use assets, operating l...
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Accrued expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-39,717
-39,164
-44,134
-60,452
Depreciation expense
805
886
1,230
1,980
Stockbased compensation expense
4,744
4,358
5,116
10,135
Amortization/(accretion) of marketable securities
548
633
739
2,299
Collaboration receivable
-390
-19
16
-2,500
Prepaid expenses and other current assets
2,461
-1,504
-3,731
-2,407
Right-of-use assets, operating leases
-1,693
-1,671
-3,559
-5,439
Other non-current assets
20
-93
-36
-85
Accounts payable
641
-877
1,309
-2,231
Accrued expenses and other current liabilities
-5,952
2,150
3,737
-1,145
Income tax payable
0
-620
620
-667
Operating lease liabilities
-1,182
-1,468
-2,343
-4,464
Deferred revenue
-88
-122
-419
-19,284
Net cash used in operating activities
-41,695
-32,203
-28,313
-67,996
Purchases of property and equipment
44
-207
-171
1,419
Purchases of marketable securities
11,825
18,473
26,566
96,574
Maturities of marketable securities
38,856
47,385
75,504
136,573
Net cash provided by investing activities
26,987
29,119
49,109
38,580
Proceeds from issuance of common stock under the employee stock purchase plan
-
145
0
317
Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs paid
-
-
0
0
Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs paid-Registered Direct Offering
-
0
-
-
Proceeds from exercise of stock options
100
47
8
370
Net cash provided by financing activities
100
192
8
687
Net decrease in cash, cash equivalents and restricted cash
-14,608
-2,892
20,804
-28,729
Cash, cash equivalents, and restricted cash at beginning of period
94,344
97,236
105,161
-
Cash, cash equivalents, and restricted cash at end of period
79,736
94,344
97,236
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$38,856K
Proceeds from exercise of
stock options
$100K
Net cash provided by
investing activities
$26,987K
Net cash provided by
financing activities
$100K
Canceled cashflow
$11,869K
Net decrease in
cash, cash...
-$14,608K
Canceled cashflow
$27,087K
Stockbased compensation
expense
$4,744K
Right-of-use assets,
operating leases
-$1,693K
Depreciation expense
$805K
Accounts payable
$641K
Collaboration receivable
-$390K
Purchases of marketable
securities
$11,825K
Purchases of property and
equipment
$44K
Net cash used in
operating activities
-$41,695K
Canceled cashflow
$8,273K
Net loss
-$39,717K
Accrued expenses and
other current...
-$5,952K
Prepaid expenses and
other current assets
$2,461K
Operating lease
liabilities
-$1,182K
Amortization/(accretion) of marketable
securities
$548K
Deferred revenue
-$88K
Other non-current
assets
$20K
Buy us a coffee